menu search

Teva to present data demonstrating uzedy™ (risperidone) extended-release injectable suspension significantly prolonged time to impending relapse for adults with schizophrenia at the american psychiatr

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TE...

May 20, 2023, 11:00 am

Teva to present data demonstrating uzedy™ (risperidone) extended-release injectable suspension significantly prolonged time to impending relapse for adults with schizophrenia at the american psychiatr

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TE...

May 20, 2023, 11:00 am

Teva to present data demonstrating uzedy™ (risperidone) extended-release injectable suspension significantly prolonged time to impending relapse for adults with schizophrenia at the american psychiatr

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TE...

May 20, 2023, 11:00 am

Teva to present data demonstrating uzedy™ (risperidone) extended-release injectable suspension significantly prolonged time to impending relapse for adults with schizophrenia at the american psychiatr

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TE...

May 20, 2023, 11:00 am

Teva to present data demonstrating uzedy™ (risperidone) extended-release injectable suspension significantly prolonged time to impending relapse for adults with schizophrenia at the american psychiatr

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TE...

May 20, 2023, 11:00 am

Teva to present data demonstrating uzedy™ (risperidone) extended-release injectable suspension significantly prolonged time to impending relapse for adults with schizophrenia at the american psychiatr

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TE...

May 20, 2023, 11:00 am

Teva to present data demonstrating uzedy™ (risperidone) extended-release injectable suspension significantly prolonged time to impending relapse for adults with schizophrenia at the american psychiatr

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TE...

May 20, 2023, 11:00 am

Teva to present data demonstrating uzedy™ (risperidone) extended-release injectable suspension significantly prolonged time to impending relapse for adults with schizophrenia at the american psychiatr

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TE...

May 20, 2023, 11:00 am

Teva to present data demonstrating uzedy™ (risperidone) extended-release injectable suspension significantly prolonged time to impending relapse for adults with schizophrenia at the american psychiatr

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TE...

May 20, 2023, 11:00 am

Teva to present data demonstrating uzedy™ (risperidone) extended-release injectable suspension significantly prolonged time to impending relapse for adults with schizophrenia at the american psychiatr

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TE...

May 20, 2023, 11:00 am

Teva to present data demonstrating uzedy™ (risperidone) extended-release injectable suspension significantly prolonged time to impending relapse for adults with schizophrenia at the american psychiatr

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TE...

May 20, 2023, 11:00 am

Oxford nanopore technologies hails advances

Oxford Nanopore Technologies PLC (LSE:ONT) has announced significant breakthroughs in its nanopore sequencing technology at the annual London Calling...

May 19, 2023, 3:02 am

: would reparations lead to irresponsible spending? studies on other cash windfalls suggest not, new report says.

Reparations payouts to Black Americans are unlikely to result in reckless spending, financial ruin and reduced labor productivity, researchers say. Re...

May 18, 2023, 4:06 pm

Mink’s novel fap-car-inkt presented at asgct

FAP-CAR-IL-15 iNKT cell therapy (MiNK-215) promotes curative responses driving tumor elimination and immune infiltration in NSCLC models IND enabling ...

May 18, 2023, 12:30 pm

Voyager therapeutics presents robust, multi-species results from preclinical studies of iv-delivered, tracer™-generated novel capsids at the asgct 26th annual meeting

Oral presentation features further evaluation of second-generation capsids, demonstrating increased transduction in several brain areas across multipl...

May 18, 2023, 10:00 am

Usd/jpy: key barriers in focus but consolidation likely to precede attack

Strong bullish acceleration extends into fifth straight day and cracks 200DMA (137.05), with key barriers at 137.77 (May 2 top) and 137.90 (Mar 8) in ...

May 17, 2023, 9:01 am

Perspective therapeutics reports first quarter fiscal 2023 results

Additional CDMO capabilities added to increase availability of clinical trial product in the US Phase I/IIa st...

May 16, 2023, 12:22 am

Psychedelic science 2023 announces sessions and select featured speakers for the therapy and practitioners tracks for june conference

Dr. Rachel Yehuda to Lead Discussions on Therapeutic Application of Psychedelics Additional Featured Speakers Include Dr. Julie Holland, Dr. Carl Hart...

May 12, 2023, 11:30 am

Immunitybio: anktiva rejection heightens financial urgency

ImmunityBio stock dropped over 50% after the FDA issued a CRL for Anktiva, their lead product for treating BCG-unresponsive non-muscle invasive bladde...

May 12, 2023, 5:20 am

Gracell biotechnologies to present clinical data on bcma/cd19 dual-targeting fastcar-t gc012f in rrmm and b-nhl and donor-derived car-t gc007g in b-all at eha2023 congress

First disclosure of data from Phase 1 study of the donor-derived allogeneic CAR-T GC007g shows 100% overall response rate (ORR) and a favorable safety...

May 11, 2023, 5:28 pm


Search within

Pages Search Results: